錦欣生殖(01951.HK)續漲逾半成首獲大摩給予「增持」評級看11元
錦欣生殖(01951.HK)首獲保薦人之一的大摩給予「增持」評級看11元,該股承昨天逆市微彈勢,今早最多漲6.6%高見9.65元,現造9.51元,續升5.1%,成交已較昨天全日成交量增逾2倍至823萬股。
錦欣生殖是中美領先的輔助生殖(人工授孕)服務供應商。股份於6月25日以每股8.54元在港上市,並已引入高瓴、匯橋、奧博及Cormorant為基石投資者,集資淨額逾28億元,上市聯席保薦人分別為大摩和中信里昂。股份於首掛日最多漲25%至10.68元遇阻,收市僅升8.7%後,股價反覆回落,7月中旬連續兩天觸及上市價8.54元均獲承接。
大摩指錦欣生殖業務遍及中美兩國,公司於2016-2018年收入及經調整純利年複合增長率分別為63%及64%,預期2018-2021年收入及經調整純利年複合增長率分別為40%及56%。此外,公司具有長期運營歷史和信譽良好的醫生,加上優化運營模式高生產率,潛在積極中美協同效應等優勢,該行首予錦欣「增持」評級,目標價11元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.